Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients
Aim The purpose of this study was to investigate the co-expression of survivin, c-erbB2, and COX-2 in endometrial cancer tissues and evaluate its prognostic significance in endometrial cancer Methods Tumor tissue biopsies from 110 patients with primary untreated endometrial carcinomas were studied b...
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2010-03, Vol.136 (3), p.427-435 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 435 |
|---|---|
| container_issue | 3 |
| container_start_page | 427 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 136 |
| creator | Lambropoulou, Maria Papadopoulos, Nikolaos Tripsianis, Grigoris Alexiadis, George Pagonopoulou, Olga Kiziridou, Anastasia Liberis, Vassilios Kakolyris, Stylianos Chatzaki, Ekaterini |
| description | Aim The purpose of this study was to investigate the co-expression of survivin, c-erbB2, and COX-2 in endometrial cancer tissues and evaluate its prognostic significance in endometrial cancer Methods Tumor tissue biopsies from 110 patients with primary untreated endometrial carcinomas were studied by immunohistochemistry. Statistical analysis evaluated correlation of antigen expression with tumor stage, grade, myometrial invasion, and histologic type. Association with disease outcome was also investigated Results The results showed that expression of the three antigens was independently associated with histological grade, disease stage, and myometrial invasion. Clinicopathological parameters were also associated with the number of antigens expressed by each tumor, the expression of more antigens correlating with advanced stage disease and deep myometrial invasion. In a 10-year follow-up, patients with tumors expressing more of these three antigens had significantly lower survival rate that those with smaller expression score Conclusions Our results indicate that the co-expression score has independent prognostic value for endometrial cancer. |
| doi_str_mv | 10.1007/s00432-009-0673-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733620581</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733620581</sourcerecordid><originalsourceid>FETCH-LOGICAL-c490t-9fb198fd09a7c05f64738f5fc47df85ab1df8e380c3f4f57a0a778959beb71fa3</originalsourceid><addsrcrecordid>eNp9kk-LFDEQxYMo7rj6AbxoI4gKG60knU7H2-7gP1jYgy54C-l0MmTpSWaT7mHn4mc3bQ8uePBUVPJ7r4q8IPScwHsCID5kgJpRDCAxNILh5gFakfmEMMYfohUQQTCnpDlBT3K-gdJzQR-jEyIFLwKxQr_WEdu7XbI5-xiq6Ko8pb3f-3BWGWxTd0HPKh36yhzMEOPdYWODzhbT6u366iem7z5WuxQ3IebRm2qvh8n-wRcXPcyONvRxa8fkS2t0MDZVOz16G8b8FD1yesj22bGeouvPn36sv-LLqy_f1ueX2NQSRixdR2TrepBaGOCuqQVrHXemFr1rue5IKZa1YJirHRcatBCt5LKznSBOs1P0ZvEty95ONo9q67Oxw6CDjVNWgrGGAm9JIV_9Q97EKYWynKKF4FzIGSILZFLMOVmndslvdTooAmqORi3RqBKNmqNRTdG8OBpP3db294pjFgV4fQR0NnpwqTyVz385ShknlEPh6MLlchU2Nt1v-L_pLxeR01HpTSrG198pEFb-hKw5b9lvxdevTA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220555791</pqid></control><display><type>article</type><title>Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Lambropoulou, Maria ; Papadopoulos, Nikolaos ; Tripsianis, Grigoris ; Alexiadis, George ; Pagonopoulou, Olga ; Kiziridou, Anastasia ; Liberis, Vassilios ; Kakolyris, Stylianos ; Chatzaki, Ekaterini</creator><creatorcontrib>Lambropoulou, Maria ; Papadopoulos, Nikolaos ; Tripsianis, Grigoris ; Alexiadis, George ; Pagonopoulou, Olga ; Kiziridou, Anastasia ; Liberis, Vassilios ; Kakolyris, Stylianos ; Chatzaki, Ekaterini</creatorcontrib><description>Aim The purpose of this study was to investigate the co-expression of survivin, c-erbB2, and COX-2 in endometrial cancer tissues and evaluate its prognostic significance in endometrial cancer Methods Tumor tissue biopsies from 110 patients with primary untreated endometrial carcinomas were studied by immunohistochemistry. Statistical analysis evaluated correlation of antigen expression with tumor stage, grade, myometrial invasion, and histologic type. Association with disease outcome was also investigated Results The results showed that expression of the three antigens was independently associated with histological grade, disease stage, and myometrial invasion. Clinicopathological parameters were also associated with the number of antigens expressed by each tumor, the expression of more antigens correlating with advanced stage disease and deep myometrial invasion. In a 10-year follow-up, patients with tumors expressing more of these three antigens had significantly lower survival rate that those with smaller expression score Conclusions Our results indicate that the co-expression score has independent prognostic value for endometrial cancer.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-009-0673-6</identifier><identifier>PMID: 19756737</identifier><identifier>CODEN: JCROD7</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antigens ; Antineoplastic agents ; Biological and medical sciences ; Biopsy ; Cancer Research ; Carcinoma - diagnosis ; Carcinoma - metabolism ; Carcinoma - mortality ; Carcinoma - pathology ; Case-Control Studies ; Cyclooxygenase 2 - metabolism ; Endometrial cancer ; Endometrial Neoplasms - diagnosis ; Endometrial Neoplasms - metabolism ; Endometrial Neoplasms - mortality ; Endometrial Neoplasms - pathology ; Female ; Female genital diseases ; Follow-Up Studies ; Gynecology. Andrology. Obstetrics ; Hematology ; Humans ; Immunohistochemistry ; Inhibitor of Apoptosis Proteins ; Internal Medicine ; Medical prognosis ; Medical sciences ; Medicine ; Medicine & Public Health ; Microtubule-Associated Proteins - metabolism ; Middle Aged ; Neoplasm Staging ; Oncology ; Original Paper ; Pharmacology. Drug treatments ; Predictive Value of Tests ; Prognosis ; Receptor, ErbB-2 - metabolism ; Survival Analysis ; Tumors</subject><ispartof>Journal of cancer research and clinical oncology, 2010-03, Vol.136 (3), p.427-435</ispartof><rights>Springer-Verlag 2009</rights><rights>2015 INIST-CNRS</rights><rights>Springer-Verlag 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c490t-9fb198fd09a7c05f64738f5fc47df85ab1df8e380c3f4f57a0a778959beb71fa3</citedby><cites>FETCH-LOGICAL-c490t-9fb198fd09a7c05f64738f5fc47df85ab1df8e380c3f4f57a0a778959beb71fa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-009-0673-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-009-0673-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22351250$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19756737$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lambropoulou, Maria</creatorcontrib><creatorcontrib>Papadopoulos, Nikolaos</creatorcontrib><creatorcontrib>Tripsianis, Grigoris</creatorcontrib><creatorcontrib>Alexiadis, George</creatorcontrib><creatorcontrib>Pagonopoulou, Olga</creatorcontrib><creatorcontrib>Kiziridou, Anastasia</creatorcontrib><creatorcontrib>Liberis, Vassilios</creatorcontrib><creatorcontrib>Kakolyris, Stylianos</creatorcontrib><creatorcontrib>Chatzaki, Ekaterini</creatorcontrib><title>Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Aim The purpose of this study was to investigate the co-expression of survivin, c-erbB2, and COX-2 in endometrial cancer tissues and evaluate its prognostic significance in endometrial cancer Methods Tumor tissue biopsies from 110 patients with primary untreated endometrial carcinomas were studied by immunohistochemistry. Statistical analysis evaluated correlation of antigen expression with tumor stage, grade, myometrial invasion, and histologic type. Association with disease outcome was also investigated Results The results showed that expression of the three antigens was independently associated with histological grade, disease stage, and myometrial invasion. Clinicopathological parameters were also associated with the number of antigens expressed by each tumor, the expression of more antigens correlating with advanced stage disease and deep myometrial invasion. In a 10-year follow-up, patients with tumors expressing more of these three antigens had significantly lower survival rate that those with smaller expression score Conclusions Our results indicate that the co-expression score has independent prognostic value for endometrial cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antigens</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Cancer Research</subject><subject>Carcinoma - diagnosis</subject><subject>Carcinoma - metabolism</subject><subject>Carcinoma - mortality</subject><subject>Carcinoma - pathology</subject><subject>Case-Control Studies</subject><subject>Cyclooxygenase 2 - metabolism</subject><subject>Endometrial cancer</subject><subject>Endometrial Neoplasms - diagnosis</subject><subject>Endometrial Neoplasms - metabolism</subject><subject>Endometrial Neoplasms - mortality</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Follow-Up Studies</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Inhibitor of Apoptosis Proteins</subject><subject>Internal Medicine</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Microtubule-Associated Proteins - metabolism</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Pharmacology. Drug treatments</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Survival Analysis</subject><subject>Tumors</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kk-LFDEQxYMo7rj6AbxoI4gKG60knU7H2-7gP1jYgy54C-l0MmTpSWaT7mHn4mc3bQ8uePBUVPJ7r4q8IPScwHsCID5kgJpRDCAxNILh5gFakfmEMMYfohUQQTCnpDlBT3K-gdJzQR-jEyIFLwKxQr_WEdu7XbI5-xiq6Ko8pb3f-3BWGWxTd0HPKh36yhzMEOPdYWODzhbT6u366iem7z5WuxQ3IebRm2qvh8n-wRcXPcyONvRxa8fkS2t0MDZVOz16G8b8FD1yesj22bGeouvPn36sv-LLqy_f1ueX2NQSRixdR2TrepBaGOCuqQVrHXemFr1rue5IKZa1YJirHRcatBCt5LKznSBOs1P0ZvEty95ONo9q67Oxw6CDjVNWgrGGAm9JIV_9Q97EKYWynKKF4FzIGSILZFLMOVmndslvdTooAmqORi3RqBKNmqNRTdG8OBpP3db294pjFgV4fQR0NnpwqTyVz385ShknlEPh6MLlchU2Nt1v-L_pLxeR01HpTSrG198pEFb-hKw5b9lvxdevTA</recordid><startdate>20100301</startdate><enddate>20100301</enddate><creator>Lambropoulou, Maria</creator><creator>Papadopoulos, Nikolaos</creator><creator>Tripsianis, Grigoris</creator><creator>Alexiadis, George</creator><creator>Pagonopoulou, Olga</creator><creator>Kiziridou, Anastasia</creator><creator>Liberis, Vassilios</creator><creator>Kakolyris, Stylianos</creator><creator>Chatzaki, Ekaterini</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20100301</creationdate><title>Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients</title><author>Lambropoulou, Maria ; Papadopoulos, Nikolaos ; Tripsianis, Grigoris ; Alexiadis, George ; Pagonopoulou, Olga ; Kiziridou, Anastasia ; Liberis, Vassilios ; Kakolyris, Stylianos ; Chatzaki, Ekaterini</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c490t-9fb198fd09a7c05f64738f5fc47df85ab1df8e380c3f4f57a0a778959beb71fa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antigens</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Cancer Research</topic><topic>Carcinoma - diagnosis</topic><topic>Carcinoma - metabolism</topic><topic>Carcinoma - mortality</topic><topic>Carcinoma - pathology</topic><topic>Case-Control Studies</topic><topic>Cyclooxygenase 2 - metabolism</topic><topic>Endometrial cancer</topic><topic>Endometrial Neoplasms - diagnosis</topic><topic>Endometrial Neoplasms - metabolism</topic><topic>Endometrial Neoplasms - mortality</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Follow-Up Studies</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Inhibitor of Apoptosis Proteins</topic><topic>Internal Medicine</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Microtubule-Associated Proteins - metabolism</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Pharmacology. Drug treatments</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Survival Analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lambropoulou, Maria</creatorcontrib><creatorcontrib>Papadopoulos, Nikolaos</creatorcontrib><creatorcontrib>Tripsianis, Grigoris</creatorcontrib><creatorcontrib>Alexiadis, George</creatorcontrib><creatorcontrib>Pagonopoulou, Olga</creatorcontrib><creatorcontrib>Kiziridou, Anastasia</creatorcontrib><creatorcontrib>Liberis, Vassilios</creatorcontrib><creatorcontrib>Kakolyris, Stylianos</creatorcontrib><creatorcontrib>Chatzaki, Ekaterini</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lambropoulou, Maria</au><au>Papadopoulos, Nikolaos</au><au>Tripsianis, Grigoris</au><au>Alexiadis, George</au><au>Pagonopoulou, Olga</au><au>Kiziridou, Anastasia</au><au>Liberis, Vassilios</au><au>Kakolyris, Stylianos</au><au>Chatzaki, Ekaterini</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2010-03-01</date><risdate>2010</risdate><volume>136</volume><issue>3</issue><spage>427</spage><epage>435</epage><pages>427-435</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><coden>JCROD7</coden><abstract>Aim The purpose of this study was to investigate the co-expression of survivin, c-erbB2, and COX-2 in endometrial cancer tissues and evaluate its prognostic significance in endometrial cancer Methods Tumor tissue biopsies from 110 patients with primary untreated endometrial carcinomas were studied by immunohistochemistry. Statistical analysis evaluated correlation of antigen expression with tumor stage, grade, myometrial invasion, and histologic type. Association with disease outcome was also investigated Results The results showed that expression of the three antigens was independently associated with histological grade, disease stage, and myometrial invasion. Clinicopathological parameters were also associated with the number of antigens expressed by each tumor, the expression of more antigens correlating with advanced stage disease and deep myometrial invasion. In a 10-year follow-up, patients with tumors expressing more of these three antigens had significantly lower survival rate that those with smaller expression score Conclusions Our results indicate that the co-expression score has independent prognostic value for endometrial cancer.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>19756737</pmid><doi>10.1007/s00432-009-0673-6</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2010-03, Vol.136 (3), p.427-435 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733620581 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Aged Aged, 80 and over Antigens Antineoplastic agents Biological and medical sciences Biopsy Cancer Research Carcinoma - diagnosis Carcinoma - metabolism Carcinoma - mortality Carcinoma - pathology Case-Control Studies Cyclooxygenase 2 - metabolism Endometrial cancer Endometrial Neoplasms - diagnosis Endometrial Neoplasms - metabolism Endometrial Neoplasms - mortality Endometrial Neoplasms - pathology Female Female genital diseases Follow-Up Studies Gynecology. Andrology. Obstetrics Hematology Humans Immunohistochemistry Inhibitor of Apoptosis Proteins Internal Medicine Medical prognosis Medical sciences Medicine Medicine & Public Health Microtubule-Associated Proteins - metabolism Middle Aged Neoplasm Staging Oncology Original Paper Pharmacology. Drug treatments Predictive Value of Tests Prognosis Receptor, ErbB-2 - metabolism Survival Analysis Tumors |
| title | Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T12%3A41%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Co-expression%20of%20survivin,%20c-erbB2,%20and%20cyclooxygenase-2%20(COX-2):%20prognostic%20value%20and%20survival%20of%20endometrial%20cancer%20patients&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Lambropoulou,%20Maria&rft.date=2010-03-01&rft.volume=136&rft.issue=3&rft.spage=427&rft.epage=435&rft.pages=427-435&rft.issn=0171-5216&rft.eissn=1432-1335&rft.coden=JCROD7&rft_id=info:doi/10.1007/s00432-009-0673-6&rft_dat=%3Cproquest_cross%3E733620581%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220555791&rft_id=info:pmid/19756737&rfr_iscdi=true |